[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bicara Therapeutics Inc (BCAX)

Bicara Therapeutics Inc (BCAX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,329,192
  • Shares Outstanding, K 65,704
  • Annual Sales, $ 0 K
  • Annual Income, $ -137,950 K
  • EBIT $ -156 M
  • EBITDA $ -155 M
  • 60-Month Beta -0.57
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.64

Options Overview Details

View History
  • Implied Volatility 75.50% (-0.99%)
  • Historical Volatility 44.72%
  • IV Percentile 3%
  • IV Rank 15.23%
  • IV High 321.03% on 09/26/25
  • IV Low 31.38% on 09/08/25
  • Expected Move (DTE 31) 0.94 (4.85%)
  • Put/Call Vol Ratio 0.06
  • Today's Volume 333
  • Volume Avg (30-Day) 139
  • Put/Call OI Ratio 2.53
  • Today's Open Interest 3,997
  • Open Int (30-Day) 4,205
  • Expected Range 18.36 to 20.23

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.75
  • Number of Estimates 7
  • High Estimate $-0.51
  • Low Estimate $-0.97
  • Prior Year $-0.50
  • Growth Rate Est. (year over year) -50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.20 +0.47%
on 05/18/26
23.99 -19.59%
on 04/23/26
-4.72 (-19.66%)
since 04/17/26
3-Month
14.15 +36.33%
on 02/19/26
24.25 -20.45%
on 04/17/26
+4.80 (+33.13%)
since 02/18/26
52-Week
7.80 +147.31%
on 05/23/25
24.25 -20.45%
on 04/17/26
+4.82 (+33.31%)
since 05/16/25

Most Recent Stories

More News
Bicara Therapeutics Touts Cancer Drug Progress Ahead of 2026 Pivotal Data

Bicara Therapeutics (NASDAQ:BCAX) said its lead cancer drug candidate, ficerafusp alfa, remains on track for pivotal data in head and neck cancer in mid-2026, as the company outlined its development strategy...

BCAX : 19.29 (-4.65%)
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with...

BCAX : 19.29 (-4.65%)
Bicara Therapeutics Q1 Earnings Call Highlights

Bicara Therapeutics (NASDAQ:BCAX) said it made progress during the first quarter of 2026 on the development and commercialization strategy for its lead drug candidate, ficerafusp alfa, or FICERA, while...

BCAX : 19.29 (-4.65%)
Bicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Study to evaluate ficerafusp alfa in combination with pembrolizumab as a loading and every-three-week maintenance regimen in 1L R/M HPV-negative HNSCC expected to initiate in Q3 2026 Long-term follow-up...

BCAX : 19.29 (-4.65%)
BCAX's Phase Three Timeline Meets the Market's Patience Threshold

Barchart Research What to Expect from BCAX Earnings BCAX Generated May 8, 2026 Current Price $22.58 EPS Estimate $$-0.64 Consensus Rating Strong Buy Average Move 5.17% BCAX's Phase Three Timeline Meets...

BCAX : 19.29 (-4.65%)
BCAX's Phase Three Timeline Meets the Market's Patience Threshold

Barchart Research What to Expect from BCAX Earnings BCAX Generated May 8, 2026 Current Price $22.58 EPS Estimate $$-0.64 Consensus Rating Strong Buy Average Move 5.17% BCAX's Phase Three Timeline Meets...

BCAX : 19.29 (-4.65%)
BCAX's Phase Three Timeline Meets the Market's Patience Threshold

Barchart Research What to Expect from BCAX Earnings BCAX Generated May 8, 2026 Current Price $22.58 EPS Estimate $$-0.64 Consensus Rating Strong Buy Average Move 5.17% BCAX's Phase Three Timeline Meets...

BCAX : 19.29 (-4.65%)
Bicara Therapeutics to Report First Quarter 2026 Financial Results and Business Updates on May 11, 2026, at 8:30 AM ET

BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with...

BCAX : 19.29 (-4.65%)
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

BOSTON, April 03, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients...

BCAX : 19.29 (-4.65%)
Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Selected 1500mg weekly of ficerafusp alfa as the optimal dose and initiated Phase 3 of the FORTIFI-HN01 pivotal trial; interim analysis expected mid-2027 Announced development of a less frequent loading...

BCAX : 19.29 (-4.65%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. The company's lead asset includes ficerafusp alfa. Bicara Therapeutics Inc. is based in BOSTON.

See More

Key Turning Points

3rd Resistance Point 22.13
2nd Resistance Point 21.52
1st Resistance Point 20.41
Last Price 19.29
1st Support Level 18.69
2nd Support Level 18.08
3rd Support Level 16.97

See More

52-Week High 24.25
Last Price 19.29
Fibonacci 61.8% 17.97
Fibonacci 50% 16.02
Fibonacci 38.2% 14.08
52-Week Low 7.80

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.